Results 31 to 40 of about 63,889 (276)

Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis

Case Reports in Dermatology, 2017
A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled ...
Yuki Matsuura-Otsuki, Takaaki Hanafusa, Hiroo Yokozeki, Kyoko Watanabe   +3 more
doaj   +1 more source

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis

Respiratory Research, 2022
Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis.
Abdullah Sakkat, Gerard Cox, Nader Khalidi, Maggie Larche, Karen Beattie, Elisabetta A. Renzoni, Nilesh Morar, Vasilis Kouranos, Martin Kolb, Nathan Hambly   +9 more
doaj   +1 more source

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients

Inflammatory Intestinal Diseases, 2021
Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD).
Manuel Sutter, Petr Hruz, Jan Hendrik Niess   +2 more
doaj   +1 more source

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

Pharmaceuticals, 2013
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns.
George Alex, Di Simpson, Anthony G. Catto-Smith, Oliver Gouldthorpe   +3 more
doaj   +1 more source

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Arthritis Research & Therapy, 2019
Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis, Fenglong Xie, Jonathan Kay, Joel D Kallich   +3 more
doaj   +1 more source

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study

Journal of Clinical Rheumatology and Immunology, 2022
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor, Ali Altaqi, Abdulnasser Abdullah, Amer Khudhairy   +3 more
doaj   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis

Frontiers in Pediatrics, 2021
Background: Data on serum infliximab concentrations during induction in pediatric ulcerative colitis are limited. The study aim is to evaluate the relationship between serum infliximab concentrations during induction and short-term clinical remission in ...
Jennifer C. C. deBruyn, Jennifer C. C. deBruyn, Kevan Jacobson, Wael El-Matary, Eytan Wine, Matthew W. Carroll, Caitlin Goedhart, Caitlin Goedhart, Remo Panaccione, Iwona T. Wrobel, Hien Q. Huynh   +10 more
doaj   +1 more source

Recurrent Streptococcus agalactiae Toxic Shock Syndrome Triggered by a Tumor Necrosis Factor-α Inhibitor [PDF]

, 2016
Streptococcal toxic shock syndrome caused by group B streptococcus (GBS) is a rare, but lethal disease. We experienced a 45-year-old woman with pustular psoriasis who developed toxic shock-like syndrome during infliximab treatment.
Saijo, Tomomi, Yoshida, Masataka, Imamura, Yoshifumi, Miyazaki, Taiga, Sawai, Toyomitsu, Takazono, Takahiro, Nishino, Tomoya, Yanagihara, Katsunori, Mukae, Hiroshi, Kohno, Shigeru, Nakamura, Shigeki, Yamamoto, Kazuko, Izumikawa, Koichi, Tashiro, Masato, Morinaga, Yoshitomo   +14 more
core   +1 more source